Page last updated: 2024-10-15
moli1901
Description
Moli1901: a 19 amino acid polycyclic peptide; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 139593411 |
| MeSH ID | M0453728 |
Synonyms (12)
| Synonym |
|---|
| antibiotic pa 48009 |
| leucopeptin |
| ancovenin, 2-l-lysine-6-(3-aminoalanine)-10-l-phenylalanine-12-l-phenylalanine-13-l-valine-15-(erythro-3-hydroxy-l-aspartic acid)-, cyclic 6-19)-imine |
| moli1901 |
| bpr0f3x56h , |
| lancovutide [inn] |
| moli 1901 |
| unii-bpr0f3x56h |
| moli-1901 |
| ancovenin, 2-l-lysine-6-(3-aminoalanine)-10-l-phenylalanine-12-l-phenylalanine-13-l-valine-15-(erythro-3-hydroxy-l-aspartic acid)-, cyclic (6->19)-imine |
| lancovutide [who-dd] |
| l-lysine, l-cysteinyl-l-lysyl-l-glutaminyl-d-cysteinyl-l-cysteinyl-3-aminoalanyl-l-phenylalanylglycyl-l-prolyl-l-phenylalanyl-(2s,3s)-2-amino-3-mercaptobutanoyl-l-phenylalanyl-l-valyl-l-cysteinyl-(3r)-3-hydroxy-l-.alpha.-aspartylglycyl-l-asparaginyl-(2s,3 |
Research Excerpts
Overview
Moli1901 is a 19 residue polycyclic peptide antibiotic. Increases chloride transport and water mobilization in airway epithelium.
| Excerpt | Reference |
|---|---|
| "Moli1901 is a 19 residue polycyclic peptide antibiotic which increases chloride transport and water mobilization in airway epithelium. " | ( Determination of the tissue distribution and excretion by accelerator mass spectrometry of the nonadecapeptide 14C-Moli1901 in beagle dogs after intratracheal instillation. Dingley, K; Dix, KJ; Molina, L; Rickert, DE; Ubick, E, 2005) |
Dosage Studied
| Excerpt | Reference |
|---|---|
| " A dose-response relationship to Moli1901 was observed in non-CF participants, but a greater range of variability within the CF participants contributed to the lack of a clear dose-response relationship in this group." | ( A phase I trial of intranasal Moli1901 for cystic fibrosis. Boyle, MP; Guggino, WB; Molina, L; Zeitlin, PL, 2004) |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (83.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 3 (50.00%) | 5.53% |
| Reviews | 1 (16.67%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 2 (33.33%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||